Why did Control Bionics (ASX:CBL) register its NeuroStrip platform with the US FDA?

Control Bionics (ASX:CBL) registered its NeuroStrip wearable device under listing number D605008 to formally establish the product within the United States medical device regulatory framework.

How is the market reacting to Control Bionics (ASX:CBL) following its FDA announcement?

Following the regulatory announcement, the Control Bionics (ASX:CBL) share price rose 4.62% to $0.066.

What does the US FDA listing mean for Control Bionics (ASX:CBL) commercially?

Control Bionics (ASX:CBL) stated that the medical-grade credential supports commercial expansion into advanced clinical rehabilitation, medical research, and human-computer interface markets.

What are the pending international regulatory applications for Control Bionics (ASX:CBL)?

Control Bionics (ASX:CBL) stated that it has submitted regulatory applications for Australia's Therapeutic Goods Administration (TGA), European CE marking under EU MDR, and registration under the United Kingdom MDR framework.

What are the core application areas for the technology platform of Control Bionics (ASX:CBL)?

Control Bionics (ASX:CBL) historically deployed its surface electromyography technology in assistive communication, but is now expanding into sports performance, general rehabilitation, and neural-signal research applications.

Lifestyle

Image for illustrative purposes only. Not a real photo.

Control Bionics secures FDA listing for NeuroStrip device

Written by Liezl GambePublished Aug 4, 2026, 4:28 AM

Control Bionics (ASX:CBL) completed US FDA medical device registration and listing D605008 for its NeuroStrip wearable platform.
Following the announcement, Control Bionics shares traded 4.62% higher at $0.066.
The regulatory milestone aims to support commercial expansion into clinical rehabilitation, research, and human-computer interface markets.

Control Bionics (ASX:CBL) has registered its NeuroStrip wearable device with the US FDA under listing number D605008.

While not required for sports performance, the listing establishes formal regulatory standing in the United States healthcare market.

"This registration builds on our 25 year plus legacy and supports our growth strategy," said Control Bionics CEO Jeremy Steele.

The company stated that pending regulatory applications include Australia's TGA, European CE marking, and United Kingdom MDR framework.

Following the announcement, the Control Bionics share price was up 4.62% at $0.066.

Control Bionics historically focused on non-invasive surface electromyography technology to assist individuals with assistive communication.

Control Bionics secures FDA listing for NeuroStrip device

Perguntas frequentes

Ativos relacionados a notícia